Supplemental data
Tables and figures included in this document:
- Supplementary Table 1: Median time to ART initiation and virologic suppression
- Supplementary Table 2. Multivariable Model of Relative Hazard of LTFU prior to competing event
- Supplementary Figure 1A, 1B, and 1C. Cumulative Incidence of ART Initiation/Loss to Follow-up and HIV Suppression/Loss to Follow-up Stratified by Enrollment Year and by (A) Enrollment CD4 count, (B) Race/Ethnicity, and (C) age.
Supplementary Table 1: Median time to ART initiation and virologic suppression*
Median time in days (95% Confidence Interval)
2003-12 2003-04 2005-06 2007-08 2009-10 2011-12
Variabl
e N=15272 N = 2920 N = 2808 N = 3274 N = 3097 N = 3173
ART initiation
19 (18-20) 27 (23-31) 27 (24-32) 26 (23-29) 18 (16-20) 6 (4-8) CD4 Category (cells/mm3)
≥500
153 (122-180)
334 (179-495)
456 (373-550)
274 (209-337)
175 (126-230)
37 (26-48) 350-499 62 (52-69)
172 (106-245)
176 (138-230)
98 (75-136)
62 (44-76)
15 (11-25) 200-349 17 (15-19) 34 (27-43) 25 (17-32) 29 (22-35) 15 (11-19) <1 (0-4)
<200 9 (8-10) 14 (12-16) 15 (13-17) 12 (10-14) 7 (4-8) <1 Race/Ethnicity
White 21 (19-24) 33 (24-42) 41 (32-55) 25 (21-35) 20 (13-25) 6 (3-9) Black 19 (18-21) 26 (22-33) 25 (21-29) 27 (23-31) 20 (16-22) 5 (3-8) Hispanic 15 (13-17) 23 (16-31) 23 (17-31) 22 (17-30) 13 (10-17) 5 (1-8) HIV
Risk
HET 17 (16-19) 29 (21-35) 24 (19-30) 22 (19-26) 14 (11-17) 4 (0-7) MSM 21 (20-23) 29 (23-36) 32 (27-40) 35 (29-44) 22 (19-27) 8 (6-10) IDU 19 (15-23) 28 (19-39) 30 (20-44) 15 (8-24) 21 (12-34) 1 (0-8) Age Category
≤30 32 (28-37) 40 (30-52) 44 (30-65) 59 (47-69) 41 (33-52) 13 (10-15) 31-40 17 (15-19) 23 (19-29) 23 (19-34) 21 (17-25) 14 (11-20) 4 (0-7) 41-50 16 (14-18) 26 (20-34) 25 (20-32) 20 (15-25) 11 (9-16) 2 (0-6)
>50 13 (11-16) 25 (15-34) 24 (14-31) 20 (14-26) 13 (8-19) <1 (0-5) Gender
Male 18 (16-19) 24 (21-29) 27 (23-32) 25 (22-29) 18 (15-20) 6 (4-8) Female 22 (20-25) 38 (28-45) 28 (23-37) 27 (20-34) 18 (13-23) 7 (0-12) Virologic suppression
142 (139-147)
165 (151-177)
178 (164-198)
160 (151-170)
132 (126-137)
121 (116-126) CD4 Category (cells/mm3)
≥500 307 640 702 442 270 175
(280-337) (467-805) (581-749) (340-548) (224-304) (160-192) 350-499
199 (185-216)
431 (328-505)
392 (315-465)
271 (237-323)
163 (148-181)
121 (112-132) 200-349
130 (124-136)
155 (134-182)
161 (133-183)
145 (134-165)
108 (97-125)
112 (101-123)
<200
112 (109-116)
118 (112-124)
127 (119-135)
110 (105-119)
104 (97-111)
106 (99-112) Race/Ethnicity
White
145 (136-152)
166 (138-198)
203 (166-237)
157 (142-175)
138 (129-154)
114 (107-126) Black
143 (138-151)
165 (143-181)
178 (160-208)
160 (145-175)
130 (119-138)
126 (119-133) Hispanic
141 (136-148)
167 (140-191)
162 (145-190)
163 (143-180)
127 (109-143)
120 (112-130) HIV
Risk HET
138 (133-143)
154 (136-171)
167 (152-198)
144 (130-159)
126 (113-135)
121 (112-131) MSM
145 (139-151)
175 (150-196)
189 (166-215)
175 (164-188)
136 (128-146)
118 (111-126) IDU
159 (147-175)
186 (154-238)
190 (148-239)
159 (133-193)
132 (115-171)
126 (108-148) Age Category
≤30
160 (151-170)
160 (135-191)
238 (200-270)
211 (189-246)
155 (139-171)
127 (115-135) 31-40
137 (131-145)
166 (139-185)
166 (151-190)
138 (123-159)
126 (109-136)
119 (110-128) 41-50
143 (136-150)
181 (155-200)
178 (154-212)
156 (143-170)
122 (112-132)
118 (106-126)
>50
129 (121-138)
132 (112-167)
138 (115-173)
138 (122-157)
112 (96-138)
123 (111-137) Gender
Male
140 (136-145)
161 (147-180)
173 (156-191)
158 (148-168)
131 (124-138)
120 (114-126) Female
151 (143-161)
170 (143-192)
199 (167-241)
167 (147-193)
132 (119-141)
125 (110-137)
*Excludes subjects that were censored or with competing event prior to ART initiation or virologic suppression
Supplementary Table 2. Multivariable Model of Relative Hazard of Loss to Follow-up (LTF) prior to competing events
LTFU prior to ART Initiation
LTFU prior to HIV Suppression
Variable SHR P value SHR P value
Enrollment Year
2003-04 Ref Ref
2005-06 1.00 (0.91 - 1.10) 0.982 1.01 (0.94 - 1.09) 0.819 2007-08 0.82 (0.75 - 0.90) <0.001 0.87 (0.81- 0.94) <0.001 2009-10 0.57 (0.51 - 0.63) <0.001 0.71 (0.66 - 0.77) <0.001 2011-12 0.39 (0.34 - 0.44) <0.001 0.55 (0.50 - 0.60) <0.001 CD4 Count
≥500 Ref Ref
350-499 0.69 (0.64 - 0.75) <0.001 0.81 (0.76 - 0.87) <0.001 200-349 0.36 (0.32 - 0.39) <0.001 0.62 (0.57 - 0.66) <0.001
<200 0.17 (0.15 - 0.19) <0.001 0.48 (0.45 - 0.51) <0.001 Age (years)
≤30 Ref Ref
31-40 0.76 (0.70 - 0.83) <0.001 0.87 (0.81 - 0.92) <0.001 41-50 0.69 (0.63 - 0.75) <0.001 0.79 (0.73 - 0.84) <0.001
>50 0.59 (0.52 - 0.67) <0.001 0.59 (0.54 - 0.65) <0.001 Gender
Female Ref Ref
Male 1.17 (1.07- 1.29) <0.001 1.23 (1.15 - 1.32) <0.001 Race/Ethnicity
White Ref Ref
Black 1.05 (0.96- 1.15) 0.295 1.00 (0.93 - 1.08) 0.981
Hispanic 0.85 (0.77- 0.95) 0.003 0.81 (0.74 - 0.88) <0.001 Other 1.40 (1.2. – 1.63) <0.001 1.28 (1.13 - 1.46) <0.001 HIV Risk
MSM Ref Ref
HET 1.19 (1.08- 1.31) <0.001 1.34 (1.25 - 1.44) <0.001 IDU 1.43 (1.28- 1.59) <0.001 1.69 (1.55 - 1.84) <0.001 Other 2.25 (1.98- 2.57) <0.001 2.31 (20.9 - 2.56) <0.001
*Statistically significant results (at a <0.05 level) are displayed in bold. Death was a competing events in both analyses. SHR: Subdistribution Hazard Ratio
Supplementary Figure 1A, 1B, and 1C. Cumulative Incidence of ART Initiation/Loss to Follow-up and HIV Suppression/Loss to Follow-up Stratified by Enrollment Year and by (A) Enrollment CD4 count, (B) Race/Ethnicity, and (C) age.*
A.
B.
C.
*The black curves represent 2003-04, orange 2005-06, blue 2007-08, and red 2009-10. The curves with the positive slope represent the cumulative incidence of ART initiation and virologic suppression where indicated. The curves with the negative slope represent the cumulative incidence of LTFU (1-cumulative incidence of LTFU).
